Deutschsprachige Gemeinschaft Dgbe3.625%22oct31 (BE0002940212) News

Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase

SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4...

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the...

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the...

Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024

SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the...

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from...

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey...

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

SCOTTSDALE, Ariz., March 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the...

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

SCOTTSDALE, Ariz., March 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”...

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no...

Form 4 - Statement of changes in beneficial ownership of securities

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory...

Form 8-K - Current report